1. Home
  2. CYCN vs AIMD Comparison

CYCN vs AIMD Comparison

Compare CYCN & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyclerion Therapeutics Inc.

CYCN

Cyclerion Therapeutics Inc.

HOLD

Current Price

$3.36

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Logo Ainos Inc.

AIMD

Ainos Inc.

N/A

Current Price

$1.48

Market Cap

11.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYCN
AIMD
Founded
2018
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
11.5M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
CYCN
AIMD
Price
$3.36
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
86.5K
22.9K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
8.26
N/A
EPS
N/A
N/A
Revenue
$2,074,000.00
$124,157.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.70
498.95
52 Week Low
$1.03
$1.26
52 Week High
$8.48
$4.44

Technical Indicators

Market Signals
Indicator
CYCN
AIMD
Relative Strength Index (RSI) 41.06 48.35
Support Level $3.04 $1.42
Resistance Level $3.42 $1.65
Average True Range (ATR) 0.49 0.08
MACD -0.03 0.02
Stochastic Oscillator 23.67 33.33

Price Performance

Historical Comparison
CYCN
AIMD

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: